We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MDM2, MDMX and p53 in oncogenesis and cancer therapy.
- Authors
Wade M; Li YC; Wahl GM; Wade, Mark; Li, Yao-Cheng; Wahl, Geoffrey M
- Abstract
The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour suppressor. However, the MDM proteins modulate and respond to many other signalling networks in which they are embedded. Recent mechanistic studies and animal models have demonstrated how functional interactions in these networks are crucial for maintaining normal tissue homeostasis, and for determining responses to oncogenic and therapeutic challenges. This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumour agents.
- Publication
Nature Reviews Cancer, 2012, Vol 13, Issue 2, p83
- ISSN
1474-175X
- Publication type
Academic Journal
- DOI
10.1038/nrc3430